Ultragenyx Pharmaceutical(US:RARE) Financial Modeling Prep·2026-03-12 21:05Core Insights - Ultragenyx Pharmaceutical is focused on developing treatments for rare and ultra-rare genetic diseases, utilizing innovative gene therapy approaches to meet unmet medical needs [1] - Bank of America Securities has reiterated a "Buy" rating for Ultragenyx, indicating that the stock's valuation does not fully reflect the potential of its pipeline, with the stock priced at $21.43 at the time of the endorsement [2] - The company announced promising results from a late-stage trial of its experimental gene therapy, which effectively manages ammonia levels in patients with a rare inherited disorder, highlighting its commitment to pioneering solutions in gene therapy [3] Market Performance - Despite positive trial results, Ultragenyx's stock price is currently $21.44, reflecting a decrease of 3.46% or $0.77, with fluctuations between a low of $21.12 and a high of $22.29 on the day [4] - Over the past year, the stock has experienced significant volatility, with a high of $42.37 and a low of $18.41 [4] - The company's market capitalization is approximately $2.07 billion, with a trading volume of around 544,561 shares on the NASDAQ, indicating a moderate level of investor interest [5]